AbbVie Stock News

AbbVie is a diversified healthcare company that has been able to strengthen its portfolio via acquisitions. AT&T has faced a lot of negative press in recent years but its fundamentals remain sound.

Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.

Shares of AbbVie NYSE: ABBV fell hard in the wake of its Q1 earnings report, but the dip is over. The market response to slowing Humira sales is overshadowed by strength in the non-Humira portfolio, r

NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.

AbbVie's revenue grew slightly in the first quarter despite Humira losing steam. The company's successors to Humira are proving worthy.

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

∴ Sponsored: Want to Retire Early?

AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO will testify on Capitol Hill.

Everyone needs solace in stability and development in the current turbulent market climate. These are seven unwavering businesses that are well-known for their fundamental capability to withstand mark

WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting in

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

Investors rarely have a reason to ignore Dividend Aristocrat stocks. That's doubly true today with inflation remaining stubbornly high.

AbbVie and Johnson & Johnson have excellent dividend track records and solid businesses. However, one of these healthcare giants has a slight edge over the other.

AbbVie is an unstoppable passive income machine. Eli Lilly offers a sizzling stock performance and a growing dividend.

Drugmaker AbbVie topped sales and earnings expectations in Q1, although those expectations were modest. The leading products in its portfolio are changing quickly, which makes it difficult to determin